Member access

4-Traders Homepage  >  Shares  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)

27
Real-time Quote. Real-time TRADEGATE AG - 10/24 10:01:45 pm
73.5990 EUR   +1.01%
2d ago MORPHOSYS : Updates its 2014 Financial Guidance
2d ago MORPHOSYS : Updates its 2014 Financial Guidance (Adhoc)
3d ago MORPHOSYS : Ad hoc: MorphoSys Updates its 2014 Financial Guidance
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra
10/20/2014 10/21/2014 10/22/2014 10/23/2014 10/24/2014 Date
68.23(c) 70.23(c) 71.55(c) 74.44(c) 72.86(c) Last
214 953 147 869 119 090 220 223 113 146 Volume
+0.32% +2.93% +1.88% +4.04% -2.12% Change
More quotes
Company
MorphoSys AG is engaged in the development of antibodies for therapeutic, diagnostic, and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development, and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
Surperformance© rating of MorphoSys AG
Trading Rating : Investor Rating :
More about the company
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 62,6 M
EBIT 2014 -13,9 M
Net income 2014 -12,2 M
Finance 2014 276 M
Yield 2014 -
Sales 2015 67,4 M
EBIT 2015 -3,50 M
Net income 2015 -7,10 M
Finance 2015 254 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 26,3x
EV / Sales 2015 24,7x
Capitalization 1 922 M
More Financials
Latest news on MORPHOSYS AG
2d ago MORPHOSYS : Updates its 2014 Financial Guidance
2d ago MORPHOSYS : Updates its 2014 Financial Guidance (Adhoc)
3d ago MORPHOSYS : Ad hoc: MorphoSys Updates its 2014 Financial Guidance
3d ago MORPHOSYS : Updates its 2014 Financial Guidance (Ad hoc)
3d ago MORPHOSYS : to Receive Milestone Payment for Guselkumab Phase 3 Program
3d ago MORPHOSYS : to Receive Milestone Payment for Guselkumab Phase 3 Program
5d ago MORPHOSYS : Announces Clinical Milestone in Ophthalmology Program
5d ago MORPHOSYS : Announces Clinical Milestone in Ophthalmology Program
10/15 MorphoSys Acquires Lanthipeptide Technology from Lanthio Pharma
10/15 MORPHOSYS : Acquires Lanthipeptide Technology from Lanthio Pharma
10/15 MORPHOSYS : Acquires Lanthipeptide Technology from Lanthio Pharma
09/15 MORPHOSYS : Receives Research Grant to Develop Novel Therapeutic Antibodies Targ..
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF